In autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), autoantibodies (AutoAbs) labeling brain neurons were reported; conversely, brain MRI alterations associated with these AutoAbs were never reported.
A utoimmune poliendocrinopathy-candidiasis-ectodermal dystrophy (APECED; OMIM 240300) is a rare monogenic disorder caused by loss of function mutations of the autoimmune regulator (AIRE) gene (1, 2) . AIRE is a crucial transcriptor factor within the thymus that enforces self-tolerance by promoting the expression of .3000 tissue-restricted antigen genes in medullary thymic epithelial cells (3, 4) . T cell progenitors with strong reactivity toward such self-antigens are deleted or functionally inactivated. Lacking AIRE function, patients with APECED predictably accumulate many autoreactive T cells, with an escape to the periphery, eventually causing the multiorgan autoimmune attack. Like other rare autoimmune recessive diseases, APECED is enriched in isolated populations such as the Finns (5, 6) , Sardinians (7) , and Iranian Jews (8) . The phenotype and age at manifestation vary widely (6, 9) , but typically the disease manifests in early childhood with chronic mucocutaneous candidiasis (CMC), followed by hypoparathyroidism (HP) and Addison disease (AD). Additional organ-specific autoimmune manifestations, including gonadal failure, hepatitis, pernicious anemia, vitiligo, alopecia, hypothyroidism, and hypophysitis, and more, such as ectodermal dystrophies, occur throughout life with variable penetrance (6, 9) . Atypical phenotypes and rare manifestations have also been reported (6, 9, 10) . Patients with APECED commonly display circulating high-titer autoantibodies (AutoAbs) against multiple tissue-specific key enzymes that may represent a useful tool for the diagnosis and follow-up of the patients. Some AutoAbs are also predictive of specific organ failure, being detectable years before the onset of the overt clinical manifestation (11) (12) (13) (14) . There is a prominent set of APECED-associated AutoAbs that target a number of important neurotransmitter enzymes, such as the aromatic L-amino acid decarboxylase (AADC) (11, 15) , tyrosine hydroxylase (TH) (16) , and tryptophan hydroxylase (TPH) (17) , which are involved in the biosynthesis of catecholamine or 5-hydroxytryptamine (5-TH), as well as the glutamic acid decarboxylase (GAD) (18) , which is the rate-limiting enzyme synthesizing g-aminobutyric acid (GABA). AutoAb reactivity against these enzymes often correlates with organ manifestations of the syndrome. For example, anti-AADC AutoAbs have been associated with hepatitis (11) , anti-TH with alopecia (16) , and anti-TPH (involved in serotonin biosynthesis) correlated with gastrointestinal dysfunction (17) . Anti-GAD AutoAbs are often found in APECED (18) , but type 1 diabetes (T1D) is only present in 12% to 18% of the patients with APECED (5), thus indicating that the prognostic and pathophysiological relevance of anti-GAD-AutoAbs seem to differ between patients with APECED and T1D. Of note, TH, TPH, and AADC are present in many catecholaminergic neurons of the peripheral nervous system and central nervous system (CNS), whereas GAD is selectively expressed in brain GABAergic neurons and pancreatic beta cells. High levels of circulating AutoAbs against GAD were found in newly diagnosed T1D (19) and various neurologic manifestations, including stiff-person syndrome (SPS), idiopathic epilepsy, cerebellar ataxia, and limbic encephalitis (20) . AutoAbs staining GABAergic neurons in rat brain sections (confirmed to react with the GAD enzyme by Western blot analysis) were associated with neurologic manifestations relevant to the function of the GABA neurons in the CNS, such as SPS and cerebellar ataxia (21) (22) (23) . Patients with APECED were found to contain AutoAbs that selectively react with rat brain neurons containing AADC, TH, TPH, or GAD (17, (24) (25) (26) . In one of our previous studies (26), we found that sera from 12 of 14 patients with APECED stained specific targets within the hypothalamic-pituitary axis, including neurons containing TH and the GHRH. More relevant, five of these patients showed GH deficiency, and four of them had AutoAbs to one or more targets in the hypothalamicpituitary axis. Moreover, a further potential clinical association was seen in two patients presenting memory defects or anxiety disorders together with AutoAbs to GAD neurons. Overall, these results suggest that hypothalamichypophyseal structures may be additional potential targets of autoimmune destruction in patients with APECED (27, 28) . In general, structural brain abnormalities related to brain neuronal AutoAbs are not reported in the APECED cohort. Hence, the aim of this study was to determine the frequency of brain volume alterations by using MRI in a homogeneous series of Sardinian patients with APECED and to correlate them with AutoAbs against GAD, 5-tryptophan hydroxylase (5-HT), and TH neurons.
Materials and Methods

Patients
Fourteen patients with APECED (8 women and 6 men; female/male ratio 1.33), followed at the Pediatric Clinic II, Cagliari, Sardinia, Italy, were examined in a cross-sectional study. This series was part of a larger cohort of 22 Sardinian patients with APECED involved in an extensive longitudinal study (9) . The median age of the patients at the time of MRI analysis was 32 years (range 18 to 48 years), and the median disease duration (defined as the period from the first disease manifestation to the day of MRI acquisition) was 26.8 years. Onset age ranged from 0.4 to 10 years (median: 3.5 years), and the median age at diagnosis was 7.9 years (age range: 4 to 20 years). Eleven of 14 patients (78.5%) were homozygous for the major Sardinian nonsense mutation R139X (7) . Almost all patients were severely affected, with multiple disease components (on average, seven or eight per patient), and the classic triad composed of CMC, HP, and AD was present in 10 of 14 patients. Uncommon or rare manifestations such as GH deficiency (five patients) (26) , chronic inflammatory demyelinating polyneuropathy (CIDP) (one patient) (10) , and metaphyseal bone dysplasia (one patient) (9) were also present. One of these patients died of chronic renal failure during the study period; another patient was a man who developed AD at the age of 30 years. An overview of the 14 patients with APECED is reported in Table 1 . The control group consisted of 14 healthy participants who were matched for age, sex, and demographic background. Serum samples from patients and controls who underwent a brain MRI examination were collected and used for immunohistochemistry, whose results were compared with the previous ones (26) . This study was approved by the ethical committee at our institution, and written consent was obtained from each participant.
Animals and tissue preparation
Sprague-Dawley male rats (n = 4, body weight 250 to 350 g; from Charles River) were housed under controlled temperature (23°C 6 2°C), light (12 hour-12 hour light-dark cycle), and relative humidity (60% 6 10%) conditions. Animals were allowed free access to water and food. Before euthanasia the rats were anesthetized (under gas anesthesia induced by isoflurane, IsoFlo, Italy) and perfused via the left ventricle with 4% paraformaldehyde in PBS (0.01 mol/L PO 4 
Immunohistochemistry
Immunohistochemistry was carried out using sera from the patients with APECED and healthy blood donors (both n = 14).
Initially, all sera were tested in rat brain sections on a single dilution range (1:60 to 1:200), then each positive serum was analyzed to identify the titer. The serum dilutions were performed in PBS containing 30 mL/L of donkey serum, 30 mL/L of rat serum, and 0.2 g/L NaN 3 . Sera were incubated overnight, followed by the secondary antibody (antihuman) conjugated with Cy3 (red fluorochrome; code number 709-165-149; Jackson Immunoresearch, West Grove, PA; dilution 1:500). To mark GABAergic, dopaminergic and serotonergic neuron populations, we performed double staining by using human sera in combination with the following primary antibodies: GAD-65 (1:500; catalogue number ab139958; Abcam Inc., Cambridge, United Kingdom), TH (1:500; catalogue number AB9702; Millipore, Temecula, CA), and 5-HT (1:300; catalogue number ab66047; Abcam Inc.). The anti-goat (code number 713-545-147) and chicken (code number: 703-545-155) secondary antibodies (from Jackson Immunoresearch), all raised in donkey, were used conjugated with Alexa Fluor488 (green fluorochrome). Immunostaining was observed with BX51 fluorescence microscope (Olympus, Milan, Italy) and photographed with a Fuji S3 Pro digital camera (Fujifilm, Milan, Italy). Table 1 Abbreviations: AH, autoimmune hepatitis; Al, alopecia; As, asplenia; E, dental enamel dysplasia; F, female; GHD, GH deficiency; HH, hypogonadotropic hypogonadism; Hyp, hypotension; K, keratopathy; M, male; MA, malabsorption; MD, metaphyseal osteodysplasia; N, nail dystrophy; n.f., not found; OB, severe constipation; OF, ovarian failure; PA, pernicious anemia; Ps, psoriasis; RRI, recurring respiratory infections; V, vitiligo. a Sibling pairs.
b Age at death. 
Volume quantification
The volumes were quantified with a semiautomated segmentation technique (Jim; Xinapse System, Leicester, UK). An experienced neuroradiologist (L.S., with 14 years of experience) performed the analysis. The software automatically calculated the volume, adding the areas identified by the operator.
Statistical analysis
The normality of each continuous variable group was tested with the Kolmogorov-Smirnov z test. The obtained measurements from MRI in correlation with the immunohistochemistry results were analyzed by two-tailed t test or the Mann-Whitney test. Continuous data were described as the mean value 6 SD, whereas non-Gaussian values were described as median and percentiles. Pearson r correlation analysis was also performed to test the potential correlation between volumetric MRI-based parameters and patient age. When the P value was ,0.05, the groups were considered significantly different from each other. Statistical analysis was performed with StatistiXL (BroadwayNedlands, WA, Australia).
Results
Immunohistochemical findings
In our previous study (26) the sera of 14 Sardinian patients with APECED were investigated, and the majority of them revealed AutoAbs reacting to GABAergic or dopaminergic neurons of the rat cerebellum and substantia nigra, respectively. After 10 years, we recollected serum samples from 12 of these patients (the other two were not available) to investigate whether the AutoAbs against GABAergic and dopaminergic neurons continued to be present and to eventually discover new positivities (i.e., AutoAbs against 5-HT neurons, which were not investigated before). Comparative analysis of the two samples per patient is summarized in Table 2 . Among the four patients previously shown to be positive for AutoAbs against GABAergic neurons of the cerebellum, three maintained the same positivity [#1, #11, and #12, shown in Fig. 1 (a)-1(c)] and one lost it (#10). Interestingly, in the current study, we revealed AutoAbs reacting to GABAergic neurons in almost all brain areas containing these neurons, including the substantia nigra , and one lost it (#1). Among the five previous AutoAb-negative patients, one (#3) revealed AutoAbs labeling GABAergic neurons, another (#6) showed autoimmune reactivity to dopaminergic and serotonergic neurons, and the other three remained negative (#5, #7, #13). Finally, regarding the two novel patients' sera (not previously investigated), they revealed AutoAbs against both dopaminergic and serotonergic neurons (#2, #9). Titer of the AutoAbs identified in this study ranged from 1:200 to 1:15,000. Of interest, when comparing the AutoAb profiles of the two serum samples taken at a 10-year interval, we noted a trend toward persistent autoimmune reactivity, with high to very high titers of AutoAbs over time ( Table 2 ). The control sera resulted without any positivity or with negligible immunostaining in all areas studied.
MRI findings
The 12 patients with APECED already investigated for AutoAbs~10 years ago and the two recently included patients were all evaluated through MRI. When the values of these 14 patients were compared with the 14 control subjects (Table 3 , P = 0.016; APECED vs. controls, respectively). Additionally, we observed a statistically significant increase in the ventricle volumes and total CSF of the patients (P , 0.0001). Relevant MRI volume changes in patients with APECED are summarized in Fig. 2 .
MRI findings and correlation with AutoAbs
Of interest, in 11 of 14 patients (78.57%) the brain alterations were associated with AutoAbs against GAD or TH and 5-HT neurons, at titer 1:200/1:15,000. Therefore, we subdivided the patient's sera into three groups (Table 4) , according to their positive immunoreactivity against neurons containing GAD (group I, n = 4), 5-HT or TH (group II, n = 7), or none of these (group III, n = 3). A statistically significant reduction in the volumes of the total brain (P = 0.028) and cerebellum (P = 0.028) was found in group I, also exhibiting statistically significant volume enlargement of both total CSF (P = 0.028) and ventricles (fourth and lateral, P = 0.028) compared with controls (Fig. 3) . Instead, the patients of the group II, when compared with their controls, showed a statistically significant increase in third (P = 0.002), fourth (P = 0.0005), and lateral (P = 0.0005) ventricle volumes and in the total CSF (P = 0.0005) (Fig. 3) but not in the cerebellum volume. The brain areas reporting statistically significant MRI volume changes in APECED patient groups are summarized in Fig. 4 . No correlations were found between age and brain volumes (Table 5 ).
AutoAbs vs. HLA
In APECED, the individual HLA class II alleles are a determinant of clinical phenotype (31) . In our previous study, we reported an apparent clinical association between HLA-DRB1*0301-DQB1* 0201, liver-kidney microsome AutoAbs (anti-CYP1A2), and autoimmune hepatitis in the Sardinian APECED cohort (9), providing further evidence of the role of HLA, in addition to the R139X AIRE mutation, in influencing the phenotype. We have also taken into account that specific HLA class II alleles may confer susceptibility to autoimmune neurologic syndromes, especially associated with GAD-AutoAbs (32) (33) (34) . In particular, a link between DQB1*02 allele and SPS was found (32, 33) ; furthermore, DQB1*02 allele was overexpressed in patients with idiopathic sporadic ataxia and polyendocrine syndromes (34) . Thus, we reviewed the HLA-DR and HLA-DQ alleles of Sardinian patients with APECED, previously reported (9) . When in the current study we analyzed HLA alleles among the 14 patients, we found that six (42.8%) shared the HLA-DQ2 allele (DQB1*0201 and DQB1*0202; Table 6 ), but its prevalence did not significantly differ from that in the healthy Sardinians (data not shown). We conclude that HLA-DQ2 allele is unlikely to be involved in neuronal autoimmunity in patients with APECED.
Discussion
In this study, we documented cerebral and cerebellum volume reductions in patients with APECED. Additionally, we observed significant ventricular enlargement, which is indirect evidence of the reduction of the cerebral volume. The brain alterations were associated with high-titer AutoAbs against GAD, 5-HT, and TH neurons in 78.57% of patients and were particularly remarkable in four of them (28.57%) positive for AutoAbs against GABAergic neurons.
In our study, patient age, which corresponds mainly to the duration of the disease, was not correlated to brain volume alterations, suggesting that the cerebral changes occur early in patients with APECED. Earlier MRI brain scans in pediatric patients with APECED performed concomitantly with the diagnosis of the disease, and longitudinal studies of larger cohorts of patients would be needed to address this issue.
Notably, at the time of the MRI scan, none of the patients was taking high-dose corticosteroids that could influence the outcome of the MRI analysis; patients with AD were receiving replacement therapy with oral hydrocortisone and fludrocortisone at a daily dosage of 12 to 15 mg/m 2 and 0.05 to 0.1 mg/day, respectively, since diagnosis of the disease in childhood.
In two patients with chronic autoimmune hepatitis, sustained remission of hepatitis in adulthood was maintained with azathioprine alone at a dosage of 1 mg/kg/day, or in combination with a low dosage of prednisolone (2.5 to 5 mg daily).
In our patients with APECED, even if highlighted in a small number because of the rarity of the disease, the correlation between brain volume alterations and high titers of neuronal AutoAbs seems to suggest an immunological basis of brain abnormalities. In keeping with this hypothesis, structural brain abnormalities have been previously reported in the systemic lupus erythematosus (SLE), a chronic multisystem autoimmune disorder characterized by the presence of hightiter AutoAbs directed against a broad range of selfnuclear antigens (35) . Significant reduction in the cerebral and corpus callosus volumes, associated with AutoAbs to anticardiolipin or antiphospholipid, was reported in patients with SLE either young or adult with or without CNS manifestations (36, 37) . Furthermore, brain volume atrophy was found in patients with newonset SLE and in patients with SLE before the occurrence of the obvious neuropsychiatric signs and symptoms, suggesting an immunological basis of volume reduction, independently of corticosteroid use and CNS involvement (38, 39) .
Autoimmune neurologic diseases may develop in patients with APECED. We previously diagnosed CIDP in a 17-year-old male patient who presented with gait ataxia and progressive muscular weakness associated with sensory loss. This case, together with a second patient with CIDP from Sicily, has been already described (10) . More recently, CIDP was recognized as a novel AIRE-mediated disease component, resulting in defective tolerance to myelin protein zero autoantigen (40) . Other reported neurologic diseases are mostly case reports of patients with APECED who developed cerebellar ataxia in adulthood or middle age (41), multiple sclerosis-like Groups 1 and 2 include patients with AutoAbs to GABAergic (n = 4) and serotonin/dopaminergic neurons (n = 7), respectively, whereas group 3 has no AutoAbs (n = 3) vs. relative age-matched controls (n = 4, 7, and 3, respectively). Means of the volumes (cm disease (42), or progressive severe myopathy (43) . In some patients, neurologic diseases were associated with the presence of AutoAbs directed to the GABA system or MRI brain changes (25, 41, 44) . Progressive spinocerebellar ataxia associated with cerebellar signal abnormalities, mild vermal atrophy, and AutoAbs to cerebellar Purkinje cells and brainstem neurons has been reported in a 24-year-old woman with APECED (41) . A case of limbic encephalitis associated with GAD-AutoAbs has been recently described in a young woman with APECED (44). Fetissov et al. (25) cited two patients with APECED with AutoAbs against GAD-or AADC/TH/TPH-containing neurons who were clinically affected by the SPS-like syndrome together with depression and Parkinsonism, respectively. AutoAbs to the GABA system have been associated with a wide spectrum of neurologic syndromes (20) , including SPS (21, (45) (46) (47) . Cerebellar ataxia is the second most common neurologic disease associated with high levels of GAD-AutoAbs (48) (49) (50) , sharing with SPS the same clinical and immunological features (50) . Both diseases are characterized by an insidious onset, usually in middle age (50 years), and slow progression, and they are both associated with other organ-specific autoimmune manifestations, mainly T1D, and a high incidence of organ-specific AutoAbs (20, 45, 49) . Brain MRI showed cerebellar atrophy in some patients (46) (47) (48) (49) (50) . In our APECED cohort, which has been followed up longitudinally for .25 years from the disease diagnosis in childhood to adulthood, none of the patients, except for the patient with CIDP, has so far presented any obvious neurologic symptom such as gait ataxia or stiffness and spasm, especially the four patients whose statistically significant cerebellum reduction was associated with AutoAbs at high titer against GABAergic neurons. The median age of the patients at MRI analysis was 32 years; because SPS and cerebellar ataxia occur mainly in patients aged .50 years (20, 47), we cannot predict whether these diseases will occur later. Prolonged clinical follow-up and electrophysiological investigations in patients, even asymptomatic, are needed to detect early any functional counterpart of the morphological abnormalities shown by MRI in the present investigation. Considering the young age of the patients and the slow progression of neurologic diseases, we are planning to include in the long-term follow-up of our patients with APECED detailed neurologic clinical evaluations and electrophysiological studies, to detect minimal motor and sensory nerve abnormalities in asymptomatic patients, and to further elucidate possible neurologic consequences of the anatomical and serological findings revealed in the current study.
Furthermore, we tried to correlate HLA-DR and DQ alleles (9) of our Sardinian patients with APECED with their serological features, but no significant association has been found. Six of 14 patients had the HLA-DQ2 allele (DQB1*0201 and DQB1*0202), which is involved in susceptibility to autoimmune neurologic syndromes, especially associated with GAD-AutoAbs (32) (33) (34) . However, the frequency of this allele among our patients with APECED (42.8%) showed no significant differences with the control subjects, suggesting that HLA-DQ2 allele is probably not involved in neuronal autoimmunity.
We previously reported memory deficit and emotional dysfunctions in two patients with APECED with AutoAbs against GABAergic neurons (26); these patients have been retested for GAD AutoAbs, and they maintained ) of (a) total brain, (b, c) cerebral areas, (d) cerebellum, (e) total liquor (CSF), and (f-h) ventricles in groups I, II, and III are reported. Groups include patients with APECED with AutoAbs against neurons containing GAD (n = 4, group I), 5-HT and TH (n = 7, group II), or none of these (n = 3, group III). The numbers of the age-matched controls are according to each group (n = 4, 7 and 3, respectively). Mann-Whitney test:
the same positivity in the cerebellum, also showing increased AutoAb levels in one case. To our knowledge, mood disorders and memory defects have not been recognized so far in APECED, but subtle or subclinical symptoms are not routinely evaluated in this syndrome. Interestingly, depression, anxiety, and mental fatigue have been reported in autoimmune AD (51) , and the monoaminergic and GABAergic system have been suggested to be strongly involved in the pathophysiology of depression and anxiety disorders (52) .
Notable, too, was the GM reduction we have found in our patients with APECED. Decreased GM volume, localized or diffuse, has been reported in patients with depression (53). We have not performed any neuropsychological or emotional testing in our patients to screen them for cognitive impairments; clearly, given the complexity of both immunological function and neuropathophysiology and the heterogeneous nature of mood disorders, additional studies are needed to ascertain the prevalence of mood disorders in patients with APECED and the association between GM reduction and AutoAbs against GABAergic, catecholaminergic, and serotonergic neurons.
Finally, regarding the possible neurotransmitters involved in the autoimmune reactions occurring in our patients, other than the GAD enzyme, AADC could be a good candidate as a possible autoantigen. Indeed, in our patients, AutoAbs reacting to dopaminergic neurons always stain also serotonergic neurons, both containing the AADC enzyme (53) . Indeed, in patients with APECED, the AADC enzyme, one of the APECEDassociated autoantigens (15) , was effectively the target of AutoAbs labeling AADC brain neurons (25, 54, 55) .
In conclusion, this study highlights two important findings: first, the manifestation of volume alterations at the brain and cerebellar level in patients with APECED, and second, the presence of AutoAbs against GAD, 5-HT, and TH neurons in the majority of patients with APECED, which were not so far previously associated with any brain change. Only a long-term clinical followup will show whether the association of anatomical and serological findings reported by us will lead to neurologic consequences in these patients.
Our findings are a valuable addition to the APECED literature and extend our knowledge of the complexity of the disease. Indeed, we propose that in APECED disease, the brain, like other organs, can be a potential target of circulating AutoAbs, with possible clinical consequences. Additional studies are needed to elucidate the pathophysiological mechanisms of structural brain abnormalities in patients with APECED. 
